BioVaxys Technology Corp.
BioVaxys is a clinical-stage biotechnology company based in Vancouver, developing viral and oncology vaccine platforms, immuno-diagnostics, and advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine. The company is engaged in research collaborations, vaccine development, and bio-production partnerships, with a focus on creating durable and broad-spectrum vaccines against major viral threats.
Industries
Nr. of Employees
small (1-50)
BioVaxys Technology Corp.
Products
Pan-sarbecovirus vaccine candidate (booster formulation)
A vaccine candidate designed as a booster administered with existing SARS-CoV-2 vaccines to elicit cross-reactive neutralizing antibodies against SARS-CoV-2 variants and related sarbecoviruses.
Haptenized autologous cell cancer vaccine (clinical-stage candidate)
Autologous cell-based vaccine platform using chemically modified (haptenized) patient-derived cells for oncology applications, intended for use with immune checkpoint inhibitors.
T-cell immune response diagnostic
A diagnostic assay intended to detect T-cell mediated immune responses to viral antigens, used to evaluate cellular immunity to SARS-CoV-2.
Pan-sarbecovirus vaccine candidate (booster formulation)
A vaccine candidate designed as a booster administered with existing SARS-CoV-2 vaccines to elicit cross-reactive neutralizing antibodies against SARS-CoV-2 variants and related sarbecoviruses.
Haptenized autologous cell cancer vaccine (clinical-stage candidate)
Autologous cell-based vaccine platform using chemically modified (haptenized) patient-derived cells for oncology applications, intended for use with immune checkpoint inhibitors.
T-cell immune response diagnostic
A diagnostic assay intended to detect T-cell mediated immune responses to viral antigens, used to evaluate cellular immunity to SARS-CoV-2.
Services
Preclinical study collaborations
Collaborative execution of preclinical vaccine studies, including assay development, animal immunizations, and neutralizing antibody endpoint analysis.
GMP clinical manufacturing via contract partners
Provision of clinical-grade vaccine manufacturing through contract-manufacturing partnerships and partner-managed GMP facility construction and operation.
Diagnostic development for cellular immunity
Development and validation of diagnostic assays to detect T-cell mediated immune responses to viral antigens.
Preclinical study collaborations
Collaborative execution of preclinical vaccine studies, including assay development, animal immunizations, and neutralizing antibody endpoint analysis.
GMP clinical manufacturing via contract partners
Provision of clinical-grade vaccine manufacturing through contract-manufacturing partnerships and partner-managed GMP facility construction and operation.
Diagnostic development for cellular immunity
Development and validation of diagnostic assays to detect T-cell mediated immune responses to viral antigens.
Expertise Areas
- Vaccine research and preclinical development
- Oncology immunotherapy and autologous cell vaccines
- Biomanufacturing for clinical supply (GMP)
- Immunodiagnostics development
Key Technologies
- Haptenized viral protein vaccines
- Depot/controlled-release formulation platform
- Recombinant protein expression and purification
- Surrogate virus neutralization assays